GlassScriptPhysician profile
Lori Beth Ranallo
NPI 1801964366
$48,289.77
in general payments reported to CMS, 2019-2025
15 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,950 · 2022: $22K · 2023: $17K · 2024: $4,077 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $5,439 · Honoraria: $2,213 · Food and Beverage: $2,097 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,625.00 |
| Travel and Lodging | $5,439.48 |
| Honoraria | $2,212.50 |
| Food and Beverage | $2,097.36 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $31,243.69 | 2021-2023 | Tukysa |
| Myriad Genetic Laboratories, INC. | $11,264.69 | 2021-2025 | Myrisk, Precisetumor |
| Pfizer INC. | $3,390.24 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $850.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $733.87 | 2023-2025 | Datroway |
| Puma Biotechnology, INC. | $125.00 | 2021 | |
| Stemline Therapeutics INC. | $120.73 | 2023 | Orserdu |
| Merck Sharp & Dohme LLC | $118.43 | 2022-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $117.79 | 2025 | Datroway |
| Genentech USA, INC. | $112.67 | 2022 | |
| Janssen Biotech, INC. | $84.99 | 2025 | Erleada |
| Coherus Oncology, INC. | $66.34 | 2021 | |
| Amgen INC. | $26.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.29 | 2024 | Entyvio |
| Novartis Pharmaceuticals Corporation | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ranallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.